Medscape is available in 5 Language Editions – Choose your Edition here.


5-Alpha-Reductase Deficiency Treatment & Management

  • Author: Jill E Emerick, MD; Chief Editor: Stephen Kemp, MD, PhD  more...
Updated: May 29, 2014

Medical Care

Caring for patients with 46,XY DSD requires parental and, when appropriate, patient, education regarding the specific developmental abnormalities found on the physical examination of the patient, contrasted with normal sexual development. This education should include an open and frank discussion of what is known, and not known, about long-term effects of gender assignment, including gender identity, gender role, and sexual satisfaction. These discussions need to begin as soon as the patient is discovered to have ambiguous genitalia, and is ideally performed by a multidisciplinary team that includes representation from pediatric endocrinology, pediatric urology or surgery, genetics, and mental health.

Although everyone agrees that an expeditious and thorough assessment in regard to the diagnosis is critical, decisions with lifelong impact, such as surgical intervention should not be rushed. Families must be afforded time to digest the information, adjust to the implications of the diagnosis, and be provided open and ready access to members of the treatment team as they work through the decision process.

Full disclosure of the diagnosis, prognosis (gender identity outcome as well as potential for fertility and sexual function), rationale with risks and benefits for proposed procedures, alternative treatments, and local clinical experience must be shared under the standard of informed consent.

Gender assignment

Multiple factors must be considered in recommending gender assignment for children born with ambiguous genitalia. These include diagnosis, genital appearance, surgical options for both cosmetic and functional outcome, potential for fertility, potential need for lifelong hormone replacement therapy, and the particular social, religious, and cultural context of the family.

The ultimate medical goal of treatment is to restore external genitalia as close to a nonambiguous appearance as possible while retaining full sensation, the ability for sexual satisfaction (to include penetrative intercourse ), and, ideally, fertility. In conditions where androgen response or synthesis leads to a DSD, such as partial androgen insensitivity syndrome (PAIS), 17-beta-hydroxysteroid dehydrogenase deficiency, and 5-alpha-reductase deficiency (5-ARD), attaining all of these goals is likely impossible. Conveying this to the parents and/or patient while being empathetic to their anxiety is essential.

Affording the child the best opportunity for a healthy long-term psychosocial development is the foundation for recommendations of gender assignment. In select cultures with high prevalence of 5-alpha-reductase deficiency, such as the Dominican Republic and Papua New-Guinea, gender role change is an accepted part of culture. Unfortunately, for most other cultures, a third gender is not accepted, suggesting that a decision for gender assignment should occur before the patient is able to make an individual choice. Although gender assignment in the newborn period may not be ideal, this well-intended, and perhaps justifiable approach is undertaken due to social as well as developmental concerns because children typically develop a sense of gender identity by age 3 years.

Proponents of early surgery for female gender assignment suggest that early gonadectomy increases the likelihood of gender satisfaction and stability and that surgical outcome is improved due to increased tissue plasticity. Opponents point out the increased likelihood of repeat surgical intervention, the irreversible nature of the procedure made at a time when patient consent is not attainable, and the high incidence of gender dysphoria and sexual dissatisfaction.

The most important message from the surgical literature is that the timing of the surgery appears to be of lesser importance than ensuring that the surgery be performed by a surgeon with extensive experience in caring for patients with DSD.[11]

Medical care

Medical care is dictated by gender assignment and surgical intervention

Hormone replacement therapy should be considered in patients raised in the male gender and is required in patients raised in the female gender that have undergone gonadectomy

In patients with 5-alpha-reductase deficiency who are raised as male, testosterone or dihydrotestosterone (DHT) therapy may increase penile length. Two doses of testosterone ester (125 mg per dose), given 3 weeks apart has been used in prepubertal children and should be considered prior to hypospadias repair.[24] Higher dose therapy (250-500 mg 1-2 times per week given for 6-36 mo) has been used in pubertal or postpubertal patients.[24, 25, 10]

If testosterone is used in a prepubertal patient, parents should be counseled over the potential to decrease final adult height secondary to androgen associated skeletal advancement

In patients with 5-alpha-reductase deficiency who are raised female, estrogen replacement therapy should be initiated at a bone age of 12 years or once an increase in gonadotropins is observed. The dose is tailored to reach adult replacement levels over a 3-4 year range. Progesterone or cycling of estrogen therapy is not required due to the absence of a uterus.

Decreased bone mineral density may be a complication for female patients who are not initiated or not maintained on appropriate estrogen replacement therapy but does not appear to be a problem for male patients with intact gonads.[26]


Surgical Care

Female gender assignment [10]

In patients with near complete enzyme dysfunction, infants have pseudovaginal perineoscrotal hypospadias, severely bifid scrotum, small phallic structure (microphallus or clitoromegaly, description designated based on gender assignment), and urogenital sinus (blind vaginal pouch).

Feminizing genitoplasty is a broad term to describe potential surgical interventions, and may include gonadectomy (removal of the testes), restructuring of the labioscrotal folds into labia, and reduction or recession of the phallus to provide a more clitoral appearance. Recent advances in surgical techniques have focused on procedures that spare the clitoral enervation; however, no long-term studies have assessed the success of these procedures.

Specific surgeries include gonadectomy, clitoroplasty with preservation of the clitoral glans and sensory input, separation of the urethra from the vagina, and construction (eg, Y-V vaginoplasty, colovaginoplasty).

Laparoscopic gonadectomy is recommended, if available. Proponents of female gender assignment recommend early gonadectomy to lessen the exposure to androgen, allowing for development of a more stable female gender identity and to avoid the associated virilization that occurs with puberty.

Although some centers advocate for a single-stage procedure, others delay vaginal reconstruction surgery until puberty when the patient is better able to perform required postsurgical care (dilatation).

Complications include the following:

  • Urinary tract complications
  • Decreased clitoral sensation
  • Vaginal and/or introital stenosis

Estrogen replacement therapy is required for the initiation of puberty. This therapy is typically started after the patient has attained a bone age of 12 years or once an increase in gonadotropin levels (leuteinizing hormone [LH] and follicle-stimulating hormone [FSH]) is noted.

Postoperative care for vaginoplasty involves the use of vaginal dilatation with moulds and for patients that underwent prepubertal vaginoplasty may require repair of introital and/or vaginal stenosis and vaginal lengthening.

Once gonadectomy has been performed, fertility is not possible, even if the patient decides on a gender-role change during adolescence or adulthood. Childbirth is not possible because no mullerian structures are present due to the presence of mullerian inhibiting substance during fetal development.

Male gender assignment [10, 27]

The same clinical description and timing considerations apply as is described for female gender assignment above.

The surgical correction of hypospadias, chordee, and/or cryptorchidism is required in most cases. The technique is determined by severity. Approaches include the following:

  • Urethroplasty (Perineoscrotal hypospadias repair is typically a multistage procedure.)
  • Repair of bifid scrotum
  • Chordee repair
  • Orchiopexy

Complications include the following:

  • Urethral fistula
  • Urethral stenosis

Micropenis is an anticipated clinical feature, defined by stretched penile length of less than 2.5 cm in a term newborn or a length of less than 7 cm in an adult male.[28, 29]

Testosterone or DHT therapy has been reported to increase penile size and virilization. The nonaromatizable nature of DHT decreases the chance for developing iatrogenic gynecomastia. However, neither DHT gel nor a long-acting injectable form of DHT are currently available in the United States.

If testosterone is administered to prepubertal children, advancing skeletal age that ultimately results in decreased final height is a risk.

In patients with 5-alpha-reductase deficiency, limited data suggest that high-dose testosterone may increase penile shaft length and circumference, increase erectile potency and ejaculatory volume, increase facial hair and muscularity, and improve a sense of well-being.[25, 24]

Various penile enhancement procedures are available and are directed at increasing penile length or circumference. Unfortunately, limited standardization of procedures and disappointing short-term and long-term patient satisfaction are reported.[29]

Significant complications associated with the surgical procedures include penile deformity, paradoxical shortening, scarring and granuloma formation, and sexual dysfunction.[29] The average increase in penile length for either medical or surgical intervention is 1-2 cm.

Patients with 5-alpha-reductase deficiency who have not undergone feminizing procedures may be fertile; however, most of this subpopulation require in vitro fertilization or other assisted-fertilization techniques.[30, 31] Sperm counts are typically very low, with abnormal spermatogenesis and thick ejaculate.



Pediatric endocrinologist

The pediatric endocrinologist is responsible for coordinating the laboratory and radiologic evaluation, reviewing the results to determine the etiology of the clinical findings from the other potential diagnoses in the differential, to include defects in gonadal development (Denys-Drash syndrome and others), testosterone production (3-beta-hydroxysteroid dehydrogenase, 17-beta-hydroxysteroid dehydrogenase), and testosterone response (partial androgen insensitivity) and for ensuring that parents feel informed and are educated leaders of the decision-making team.

In addition, the pediatric endocrinologist is responsible for instituting and following hormone replacement when clinically indicated. Many pediatric endocrine offices offer a multidisciplinary team approach, which may assist the family as the child matures.

Pediatric surgeon or pediatric urologist

The pediatric surgeon or pediatric urologist assesses the potential for surgical reconstruction as either male or female based on physical examination, laboratory, and radiologic information. This assessment has significant impact on helping the family make a gender assignment choice. No matter the choice, surgery is likely to be part of the treatment plan, and coordination of the timing and staging for the initial and/or subsequent procedures should be a part of the initial discussion. Surgical planning should begin at birth, but time is available to decide on the appropriate procedure based on family comfort, decreased anesthesia risk, and other issues.


The geneticist is responsible for verifying the karyotype and discussing with the family the male-limited autosomal recessive inheritance pattern for the disorder, to include the recurrence risk of 1:8 for each subsequent pregnancy. Due to a higher incidence in consanguinity, the geneticist is best prepared to interview families for this potential and to provide appropriate counseling. In families with no known genetic risk, many parents have a feeling of guilt at the birth of a child with the disorder. In this situation, emphasize to the family that nothing was missed or could have been done differently during the pregnancy to alter the outcome, but that prenatal diagnosis is an option in future pregnancies.

Child psychiatrist or pediatric psychologist

The child psychiatrist or pediatric psychologist should be involved from the beginning. These mental health professionals can help the family work with psychological issues (eg, any feelings of guilt or blame) that accompany the birth of a child with 5-alpha-reductase type 2 deficiency and help facilitate communication between the family and the medical consultants.

A child psychiatrist or pediatric psychologist with experience working with disorders of sexual development can provide emotional support for the family, can help the family formulate questions, and can be the counselor for the family and patient for issues regarding gender identity, gender role, gender satisfaction and potential change in gender role. A long-term relationship with such a support system may ensure that information about the diagnosis and treatment is provided in an age-appropriate fashion, hopefully decreasing fears and misconceptions.

Contributor Information and Disclosures

Jill E Emerick, MD Staff Pediatric Endocrinologist, Walter Reed National Military Medical Center, Assistant Professor of Pediatrics, Uniformed Services University of the Health Sciences

Jill E Emerick, MD is a member of the following medical societies: American Academy of Pediatrics, Endocrine Society, Pediatric Endocrine Society

Disclosure: Nothing to disclose.


Andrew J Bauer, MD Director, The Thyroid Center, Division of Endocrinology, The Children's Hospital of Philadelphia

Andrew J Bauer, MD is a member of the following medical societies: American Academy of Pediatrics, American Thyroid Association, Pediatric Endocrine Society, Endocrine Society

Disclosure: Nothing to disclose.

Noelle Summers Larson, MD Fellow in Pediatric Endocrinology, Uniformed Services University of the Health Sciences; Attending Physician, Department of Pediatrics, Walter Reed Army Medical Center/National Naval Medical Center

Noelle Summers Larson, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Clinical Endocrinologists, American Medical Association, Endocrine Society, Pediatric Endocrine Society

Disclosure: Nothing to disclose.

Ruth S Faircloth, MD Assistant Professor of Pediatrics, Uniformed Services University of the Health Sciences; Fellow in Pediatric Endocrinology, Walter Reed National Military Medical Center

Ruth S Faircloth, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Barry B Bercu, MD Professor, Departments of Pediatrics, Molecular Pharmacology and Physiology, University of South Florida College of Medicine, All Children's Hospital

Barry B Bercu, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Clinical Endocrinologists, American Medical Association, American Pediatric Society, Association of Clinical Scientists, Endocrine Society, Florida Medical Association, Pediatric Endocrine Society, Society for Pediatric Research, Southern Society for Pediatric Research, Society for the Study of Reproduction, American Federation for Clinical Research, Pituitary Society

Disclosure: Nothing to disclose.

Chief Editor

Stephen Kemp, MD, PhD Former Professor, Department of Pediatrics, Section of Pediatric Endocrinology, University of Arkansas for Medical Sciences College of Medicine, Arkansas Children's Hospital

Stephen Kemp, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Association of Clinical Endocrinologists, American Pediatric Society, Endocrine Society, Phi Beta Kappa, Southern Medical Association, Southern Society for Pediatric Research

Disclosure: Nothing to disclose.

Additional Contributors

Phyllis W Speiser, MD Chief, Division of Pediatric Endocrinology, Steven and Alexandra Cohen Children's Medical Center of New York; Professor of Pediatrics, Hofstra-North Shore LIJ School of Medicine at Hofstra University

Phyllis W Speiser, MD is a member of the following medical societies: American Association of Clinical Endocrinologists, Endocrine Society, Pediatric Endocrine Society, Society for Pediatric Research

Disclosure: Nothing to disclose.

  1. [Guideline] Houk CP, Lee PA. Consensus statement on terminology and management: disorders of sex development. Sex Dev. 2008. 2(4-5):172-80. [Medline].

  2. Silver RI, Russell DW. 5alpha-reductase type 2 mutations are present in some boys with isolated hypospadias. J Urol. 1999 Sep. 162(3 Pt 2):1142-5. [Medline].

  3. Imperato-McGinley J, Zhu YS. Androgens and male physiology the syndrome of 5alpha-reductase-2 deficiency. Mol Cell Endocrinol. 2002 Dec 30. 198(1-2):51-9. [Medline].

  4. Zhu YS, Imperato-McGinley JL. 5alpha-reductase isozymes and androgen actions in the prostate. Ann N Y Acad Sci. 2009 Feb. 1155:43-56. [Medline].

  5. Russell DW, Wilson JD. Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochem. 1994. 63:25-61. [Medline].

  6. Thigpen AE, Davis DL, Milatovich A, Mendonca BB, Imperato-McGinley J, Griffin JE. Molecular genetics of steroid 5 alpha-reductase 2 deficiency. J Clin Invest. 1992 Sep. 90(3):799-809. [Medline].

  7. Azzouni F, Godoy A, Li Y, Mohler J. The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases. Adv Urol. 2012. 2012:530121. [Medline]. [Full Text].

  8. Maimoun L, Philibert P, Bouchard P, Ocal G, Leheup B, Fenichel P. Primary amenorrhea in four adolescents revealed 5a-reductase deficiency confirmed by molecular analysis. Fertil Steril. 2011 Feb. 95(2):804.e1-5. [Medline].

  9. Costa EM, Domenice S, Sircili MH, Inacio M, Mendonca BB. DSD due to 5a-reductase 2 deficiency - from diagnosis to long term outcome. Semin Reprod Med. 2012 Oct. 30(5):427-31. [Medline].

  10. Medonca BB, Domenice S, Arnhold, JP, and Costa EMF. 46, XY disorders of sex development (DSD). Clinical Endocrinology. 2009. 70:173-187.

  11. Allen L. Disorders of Sexual Development. Obstet Gynecol Clin N Am. 2009. 36:25-45.

  12. Bertelloni S, Scaramuzzo RT, Parrini D, Baldinotti F, Tumini S, Ghirri P. Early diagnosis of 5alpha-reductase deficiency in newborns. Sex Dev. 2007. 1(3):147-51. [Medline].

  13. Maimoun L, Philibert P, Bouchard P, Ocal G, Leheup B, Fenichel P. Primary amenorrhea in four adolescents revealed 5a-reductase deficiency confirmed by molecular analysis. Fertil Steril. 2011 Feb. 95(2):804.e1-5. [Medline].

  14. Skordis N, Shammas C, Efstathiou E, Sertedaki A, Neocleous V, Phylactou L. Late diagnosis of 5alpha steroid-reductase deficiency due to IVS12A>G mutation of the SRD5a2 gene in an adolescent girl presented with primary amenorrhea. Hormones (Athens). 2011 Jul-Sep. 10(3):230-5. [Medline].

  15. Fénichel P, Paris F, Philibert P, Hiéronimus S, Gaspari L, Kurzenne JY. Molecular diagnosis of 5a-reductase deficiency in 4 elite young female athletes through hormonal screening for hyperandrogenism. J Clin Endocrinol Metab. 2013 Jun. 98(6):E1055-9. [Medline].

  16. Wilson BE, Reiner WG. Management of intersex: a shifting paradigm. J Clin Ethics. 1998 Winter. 9(4):360-9. [Medline].

  17. Tamar-Mattis A. Medical decision making in the child with a DSD. Available at Accessed: 15 May 2014.

  18. Cohen-Kettenis PT. Gender change in 46,XY persons with 5alpha-reductase-2 deficiency and 17beta-hydroxysteroid dehydrogenase-3 deficiency. Arch Sex Behav. 2005 Aug. 34(4):399-410. [Medline].

  19. Praveen EP, Desai AK, Khurana ML, et al. Gender identity of children and young adults with 5alpha-reductase deficiency. J Pediatr Endocrinol Metab. 2008 Feb. 21(2):173-9. [Medline].

  20. Maimoun L, Philibert P, Cammas B, Audran F, Bouchard P, Fenichel P. Phenotypical, biological, and molecular heterogeneity of 5a-reductase deficiency: an extensive international experience of 55 patients. J Clin Endocrinol Metab. 2011 Feb. 96(2):296-307. [Medline].

  21. Katz MD, Cai LQ, Zhu YS, et al. The biochemical and phenotypic characterization of females homozygous for 5 alpha-reductase-2 deficiency. J Clin Endocrinol Metab. 1995 Nov. 80(11):3160-7. [Medline].

  22. Choi JH, Kim GH, Seo EJ, Kim KS, Kim SH, Yoo HW. Molecular analysis of the AR and SRD5A2 genes in patients with 46,XY disorders of sex development. J Pediatr Endocrinol Metab. 2008 Jun. 21(6):545-53. [Medline].

  23. Essoterix Endocrinology Syllabus. hCG stumulaton testing. Available at Accessed: 05/13/2014.

  24. Mendonca BB, Inacio M, Costa EM, et al. Male pseudohermaphroditism due to steroid 5alpha-reductase 2 deficiency. Diagnosis, psychological evaluation, and management. Medicine (Baltimore). 1996 Mar. 75(2):64-76. [Medline].

  25. Price P, Wass JA, Griffin JE, et al. High dose androgen therapy in male pseudohermaphroditism due to 5 alpha- reductase deficiency and disorders of the androgen receptor. J Clin Invest. 1984 Oct. 74(4):1496-508. [Medline].

  26. Sobel V, Schwartz B, Zhu YS, Cordero JJ, Imperato-McGinley J. Bone mineral density in the complete androgen insensitivity and 5alpha-reductase-2 deficiency syndromes. J Clin Endocrinol Metab. 2006 Aug. 91(8):3017-23. [Medline].

  27. Sharma S, K Gupta D. Male genitoplasty for intersex disorders. Adv Urol. 2008. 685897. [Medline]. [Full Text].

  28. Ghanem H, Shamloul R, Khodeir F, ElShafie H, Kaddah A, Ismail I. Structured management and counseling for patients with a complaint of a small penis. J Sex Med. 2007 Sep. 4(5):1322-7. [Medline].

  29. Vardi Y, Har-Shai Y, Gil T, Gruenwald I. A critical analysis of penile enhancement procedures for patients with normal penile size: surgical techniques, success, and complications. Eur Urol. 2008 Nov. 54(5):1042-50. [Medline].

  30. Katz MD, Kligman I, Cai LQ, et al. Paternity by intrauterine insemination with sperm from a man with 5alpha-reductase-2 deficiency. N Engl J Med. 1997 Apr 3. 336(14):994-7. [Medline].

  31. Kang HJ, Imperato-McGinley J, Zhu YS, Cai LQ, Schlegel P, Palermo G. The first successful paternity through in vitro fertilization-intracytoplasmic sperm injection with a man homozygous for the 5a-reductase-2 gene mutation. Fertil Steril. 2011 May. 95(6):2125.e5-8. [Medline].

  32. hCG Stimulation Test. Available at Accessed: 11/09/2009.

Biochemical effects of 5-alpha-reductase type 2 deficiency in testosterone biosynthesis. Typically levels of testosterone are elevated, whereas levels of dihydrotestosterone (DHT) are significantly decreased, leading to male undervirilization.
Prader scale reflecting the degree of virilization of the external genitalia. The internal genitalia reflect the changes in the urogenital sinus in response to the presence or absence of mullerian inhibiting hormone (MIH)
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.